|
21 Mar 2007 |
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
|
|
21 Mar 2007 |
Cell Therapeutics Inc. (CTI) Files for Special Protocol Assessment (SPA) for XYOTAX(TM) PGT307 Lung Cancer Trial in Women
|
|
21 Mar 2007 |
Avexa Limited (AVX.AX) Reports Positive Phase IIb Results
|
|
21 Mar 2007 |
Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
|
|
21 Mar 2007 |
Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
|
|
20 Mar 2007 |
Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet Primary Endpoint
|
|
20 Mar 2007 |
ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
|
|
20 Mar 2007 |
Neuropharma presents advances in the development of NP-61 at the Alzheimer's and Parkinson's Diseases International Conference
|
|
20 Mar 2007 |
Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
|
|
20 Mar 2007 |
Akesis Pharmaceuticals Obtains Exclusive License for Proprietary Clinical Stage Diabetes Therapy from the University of British Columbia
|
|
20 Mar 2007 |
New Phase IV Clinical Study Indicates LidoSite(R) Provides Rheumatology Patients Superior Pain Relief
|
|
20 Mar 2007 |
In new study, Duloxetine reduced non-specific pain and emotional symptoms associated with depression
|
|
20 Mar 2007 |
Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Disease Conference
|
|
20 Mar 2007 |
Corcept Therapeutics Inc. Announces Phase 3 Study Evaluating CORLUX(R) for Psychotic Major Depression Misses Primary Endpoint
|
|
20 Mar 2007 |
Advanced Magnetics Completes Enrollment in Final Planned Phase III Study of Ferumoxytol as an IV Iron Replacement Therapeutic
|
|
19 Mar 2007 |
SEROQUEL(R) Sustained Release Schizophrenia Data presented at ECP Congress in Madrid
|
|
17 Mar 2007 |
Abeille Licenses AB-1001 to SymBio Pharmaceuticals for Commercialization in Japan and Pacific Rim Countries
|
|
17 Mar 2007 |
Amicus Therapeutics, Inc. Completes Phase 2 Enrollment of Amigal(TM) for Fabry Disease
|
|
17 Mar 2007 |
Exelixis Files IND Application for XL147
|
|
17 Mar 2007 |
Diffusion Pharmaceuticals Initiates Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC)
|
|
17 Mar 2007 |
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
|
|
17 Mar 2007 |
Nippon Shinyaku and Teva terminate HMN-214 License Agreement
|
|
16 Mar 2007 |
Trimeris and Roche Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors
|
|
16 Mar 2007 |
Acura Pharmaceuticals, Inc. Updates OxyADF Tablets Development Program and Results of Study AP-ADF-102
|
|
16 Mar 2007 |
Eli Lilly Withdraws Its Marketing Authorization Application for Arxxant
|
